DelveInsight has launched a new report on "Xerostomia-Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Xerostomia–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Xerostomia, historical and forecasted epidemiology as well as the Xerostomia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Report:
-
According to the study prevalence of xerostomia was 16% (patients with XI scores 10) and the prevalence of hyposalivation was 31% (patients with stimulated salivary flow rate 0.7 ml/min).
-
According to the observation that the prevalence of xerostomia ranged from 17% to 40% among community-dwelling elders and 20% to 72% among institutionalized elders. The prevalence of hyposalivation ranged from 15% to 23% in the community-dwelling elders and 17% to 50% among institutionalized elders
-
According to the observation, the prevalence of xerostomia ranged from 0.9% to 64.8%. The majority of data collected for these studies was in Scandinavia (most patients age greater than 50, the rest being over 18).
Key benefits of the report:
1.The Xerostomia market report covers a descriptive overview and comprehensive insight of the Xerostomia epidemiology and Xerostomia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2.The Xerostomia market report provides insights into the current and emerging therapies.
3.Xerostomia market report provides a global historical and forecasted market covering drug outreach in 7MM.
4.The Xerostomia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Xerostomia market.
Request for sample pages: https://www.delveinsight.com/sample-request/xerostomia-market
Xerostomia: Overview
Xerostomia is defined as the “complaint of oral dryness”. It can occur due to inadequate salivary secretion secondary to abnormal function of the salivary glands, which is categorized as “true” xerostomia; however, most patients with xerostomia often do not have objective signs of hyposalivation.“Symptomatic” xerostomia or “pseudo” xerostomia refers to oral dryness despite normal salivary gland function.
Patients with xerostomia can have clinical manifestations of difficulty in swallowing, chewing, and/or speaking and can present with a burning mouth, halitosis, altered taste, dry buccal mucosa, glossitis, cracked and peeled lips, oral candidiasis, and dental caries despite good oral hygiene.
The key players involved in the Xerostomia market:
-
Lubris BioPharma
-
MeiraGTx
The launch of the emerging therapies is expected to significantly impact the Xerostomia treatment scenario in the upcoming years:-
Drug covered
-
LBS020
-
AAV-AQP1
Request a free sample report @https://www.delveinsight.com/sample-request/xerostomia-market
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Xerostomia Patient Share (%) Overview at a Glance
5. Xerostomia Market Overview at a Glance
6. Xerostomia Disease Background and Overview
7. Xerostomia Epidemiology and Patient Population
8. Country-Specific Patient Population of Xerostomia
9. Xerostomia Current Treatment and Medical Practices
10. Unmet Needs
11. Xerostomia Emerging Therapies
12. Xerostomia Market Outlook
13. Country-Wise Xerostomia Market Analysis (2017–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Xerostomia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Xerostomia-Pipeline Insights, 2021
"Xerostomia-Pipeline Insight, 2021" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Xerostomia market. A detailed picture of the Xerostomia pipeline landscape is provided, which includes the disease overview and Xerostomia treatment guidelines.
Xerostomia-Epidemiology Forecast to 2030
DelveInsight's 'Xerostomia-Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Xerostomia{;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
